Role of LncRNA H19 in tumor progression and treatment

• Published in: Molecular and cellular probes Vol. 75; p. 101961
• Main Authors: Li, Linjing, Gao, Yuting, Yu, Boyi, Zhang, Jiahao, Ma, Guorong, Jin, Xiaodong
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2024; Elsevier
• Subjects: Cancer therapy; carcinogenesis; cell differentiation; drug therapy; embryogenesis; immunotherapy; LncRNA H19; metastasis; neoplasm progression; neoplasms; oncogenes; prognosis; radiotherapy; Tumorigenesis; LncRNA H19; Cancer therapy; Tumorigenesis
• ISSN: 0890-8508; 1096-1194; 1096-1194
• DOI: 10.1016/j.mcp.2024.101961

As one of the earliest discovered lncRNA molecules, lncRNA H19 is usually expressed in large quantities during embryonic development and is involved in cell differentiation and tissue formation. In recent years, the role of lncRNA H19 in tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression is closely related to cancer development. LncRNA H19 as an oncogene not only promotes the growth, proliferation, invasion and metastasis of many tumors, but also develops resistance to treatment, affecting patients' prognosis and survival. Therefore, in this review, we summarise the extensive research on the involvement of lncRNA H19 in tumor progression and discuss how lncRNA H19, as a key target gene, affects tumor sensitivity to radiotherapy, chemotherapy and immunotherapy by participating in multiple cellular processes and regulating multiple signaling pathways, which provides a promising prospect for further research into the treatment of cancer. •LncRNA H19 is a major contributor to tumorigenesis and development.•LncRNA H19 is take pary in many different cellular processes, including cancer cell proliferation, EMT, and angiogenesis.•LncRNA H19 inhibits radiation sensitivity and promotes chemotherapy resistance.•LncRNA H19 plays an important role in cancer immunotherapy through its miRNA pathway.